Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome.

Previous study indicated that antiangiogenic photodynamic therapy (PDT), laser irradiation at 15 min post-injection of photosensitizer in vivo, is effective for cancer treatment, and a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD-MA), encapsulated in polycation liposomes (PCLs), liposomes modified with cetylated polyethylenimine (cetyl-PEI), is more effective than BPD-MA encapsulated in non-modified liposomes [Cancer 97 (2003) 2027]. In the present study, we examined intracellular distribution of BPD-MA. BPD-MA encapsulated in liposomes or in PCLs was incubated with human endothelial cell line ECV304 cells or human umbilical vein endothelial cells (HUVECs), and monitored the intracellular distribution of BPD-MA by confocal laser scan microscopy.

Polycation liposome enhances the endocytic uptake of photosensitizer into cells in the presence of serum.

To construct a novel drug delivery carrier that possesses high therapeutic efficacy with low dosage, we designed polyethylenimine-modified liposome (polycation liposome, PCL) and examined the entrapment of photosensitizer, benzoporphyrin derivative monoacid ring A (BPD-MA), for antiangiogenic photodynamic therapy (PDT). Photosensitizer entrapped in PCLs showed enhanced phototoxicity for a human vascular endothelial cell line, ECV304, in comparison with that for nonmodified control liposome. Interestingly, phototoxicity of control liposomal BPD-MA was suppressed in the presence of serum, but PCL maintained the phototoxicity in the presence of serum following PCL-mediated PDT treatment due to the stability of PCL and the reduced detachment of encapsulated photosensitizer from liposome to serum.